The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1277
Two New Drugs for HIV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Raltegravir (Isentress – Merck), the first in a new class of oral HIV drugs called HIV-1 integrase strand transfer inhibitors (InSTI), has received accelerated FDA approval for use in combination therapy for treatment- experienced adults infected with HIV-1 strains resistant to multiple antiretroviral agents.1

Maraviroc (Selzentry – Pfizer), the first CCR5 (CC chemokine receptor 5) antagonist has received the same FDA approval but is restricted to use in adults with CCR5-tropic HIV-1 (“R5 virus”). A commercial assay is available for R5 tropism.

MECHANISM OF ACTION — HIV-1 integrase catalyzes the process that results in viral DNA insertion into the host cell genome. Raltegravir inhibits the enzyme’s activity, preventing viral DNA from integrating with cellular DNA. It is active against HIV strains resistant to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for HIV Infection
Article code: 1277b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian